nsMRA plus SGLT2 inhibitor combination therapy reduces ACR by approximately 33% in CKD patientsCombination therapy shows better kidney protection for chronic disease

This meta-analysis evaluated the efficacy and safety of combination therapy involving non-steroidal mineralocorticoid receptor antagonists (nsMRA) and SGLT2 inhibitors in a population of 1835 adults with chronic kidney disease (CKD) and albuminuria. The study aimed to determine if the addition of an nsMRA to an existing SGLT2 inhibitor regimen provided superior outcomes compared to SGLT2 inhibitor monotherapy.

The primary outcome measured was changes in the albumin-creatinine ratio (ACR). The analysis found that patients receiving the nsMRA plus SGLT2 inhibitor combination therapy experienced a greater reduction in ACR compared to those receiving SGLT2 inhibitor monotherapy. The reported effect size for this reduction was a ROM of 0.67 (95% CI 0.63-0.72), which corresponds to an approximate 33% reduction in ACR.

Secondary outcomes included categorical ACR responses and laboratory markers. The likelihood of achieving a 30% reduction in ACR was significantly higher with combination therapy (RR = 1.36). Furthermore, the likelihood of achieving a 50% reduction in ACR was significantly higher with combination therapy (RR = 1.76). Regarding renal function, the analysis found no overall effect on the estimated glomerular filtration rate (eGFR).

Safety and tolerability data indicated a nuanced profile for combination therapy. While the overall rates of adverse events (AEs) and serious adverse events (SAEs) were comparable to monotherapy, there were specific risks associated with the nsMRA component. Specifically, patients on combination therapy showed a modest increase in serum potassium (MD = 0.11 mmol/L). More significantly, there was a significantly higher risk of hyperkalemia in both the short- and long-term for those on combination therapy (RR = 1.55).

These results provide a nuanced view of dual-pathway inhibition in CKD. While the combination therapy appears to offer a more robust reduction in albuminuria than monotherapy, the trade-off involves a measurable increase in potassium-related risks. These findings are relevant for clinicians managing patients where albuminuria reduction is a primary goal but where potassium management is a concern.

Several methodological limitations were identified in this meta-analysis. These include a reliance on surrogate endpoints rather than hard clinical outcomes, inherent heterogeneity among the included studies, and a lack of extensive long-term data. These factors necessitate a cautious interpretation of the results.

Clinically, the data suggest that nsMRA plus SGLT2 inhibitor therapy may provide a clinically meaningful reduction in albuminuria for patients with CKD and albuminuria. However, this must be balanced against the increased risk of hyperkalemia. Practitioners should weigh the benefits of enhanced ACR reduction against the necessity for diligent potassium monitoring in patients receiving combination therapy.

Several questions remain for future investigation. Specifically, the long-term impact of this combination on hard clinical endpoints, such as the progression to end-stage kidney disease or cardiovascular events, remains unknown. Additionally, the optimal dosing and monitoring intervals to mitigate hyperkalemia while maintaining the benefits of combination therapy require further clarification in larger, long-term clinical outcome trials.